Elanco Animal Health (NYSE:ELAN) — Market Cap & Net Worth
Market Cap & Net Worth: Elanco Animal Health (ELAN)
Elanco Animal Health (NYSE:ELAN) has a market capitalization of $10.85 Billion ($10.85 Billion) as of June 17, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #2141 globally and #795 in its home market, demonstrating a 2.79% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Elanco Animal Health's stock price $24.29 by its total outstanding shares 499449583 (499.45 Million). Review ELAN current and long-term liabilities to assess the company's total debt and financial obligations.
Elanco Animal Health Market Cap History: 2018 to 2026
Elanco Animal Health's market capitalization history from 2018 to 2026. Data shows change from $15.75 Billion to $12.10 Billion (-4.96% CAGR).
Index Memberships
Elanco Animal Health is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.26 Trillion | 0.33% | #16 of 24 |
Weight: Elanco Animal Health's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Elanco Animal Health Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Elanco Animal Health's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.40x
Elanco Animal Health's market cap is 2.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $15.75 Billion | $3.07 Billion | $86.50 Million | 5.13x | 182.05x |
| 2019 | $14.71 Billion | $3.07 Billion | $67.90 Million | 4.79x | 216.62x |
| 2020 | $15.32 Billion | $3.27 Billion | -$560.10 Million | 4.68x | N/A |
| 2021 | $14.17 Billion | $4.76 Billion | -$483.00 Million | 2.98x | N/A |
| 2022 | $6.10 Billion | $4.41 Billion | -$78.00 Million | 1.38x | N/A |
| 2023 | $7.44 Billion | $4.42 Billion | -$1.23 Billion | 1.68x | N/A |
| 2024 | $6.05 Billion | $4.44 Billion | $338.00 Million | 1.36x | 17.89x |
| 2025 | $11.30 Billion | $4.71 Billion | -$232.00 Million | 2.40x | N/A |
Competitor Companies of ELAN by Market Capitalization
Companies near Elanco Animal Health in the global market cap rankings as of June 17, 2026.
Key companies related to Elanco Animal Health by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #512 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #613 globally with a market cap of $44.69 Billion USD ( CN¥305.43 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #629 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #512 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.41 |
| #613 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.69 Billion | CN¥47.88 |
| #629 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Elanco Animal Health Historical Marketcap From 2018 to 2026
Between 2018 and today, Elanco Animal Health's market cap moved from $15.75 Billion to $ 12.10 Billion, with a yearly change of -4.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.10 Billion | +7.07% |
| 2025 | $11.30 Billion | +86.87% |
| 2024 | $6.05 Billion | -18.72% |
| 2023 | $7.44 Billion | +21.93% |
| 2022 | $6.10 Billion | -56.94% |
| 2021 | $14.17 Billion | -7.47% |
| 2020 | $15.32 Billion | +4.14% |
| 2019 | $14.71 Billion | -6.60% |
| 2018 | $15.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of Elanco Animal Health was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.85 Billion USD |
| MoneyControl | $10.85 Billion USD |
| MarketWatch | $10.85 Billion USD |
| marketcap.company | $10.85 Billion USD |
| Reuters | $10.85 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide … Read more